Company Overview and News

 
DBE Gurney, KLCC Stapled Group, Salcon, TFP Solutions, Pasdec, GHL Systems, Nova MSC and Xinghe

2018-07-16 theedgemarkets
KUALA LUMPUR (July 16): Based on corporate announcements and news flow today, companies that may be in focus on Tuesday (July 17) may include the following: DBE Gurney Resources Bhd, KLCC Stapled Group, Salcon Bhd, TFP Solutions Bhd, Pasdec Holdings Bhd, GHL Systems Bhd, Nova MSC Bhd and Xinghe Holdings Bhd.
6912 0145 0026 BSMAF 0095 0021 1818

 
Xinghe aborts private placement plans

2018-07-16 theedgemarkets
KUALA LUMPUR (July 16): Xinghe Holdings Bhd has aborted its planned private placement of up to 10% of its issued share capital to raise up to RM18.32 million.
BSMAF 0095 1818

1
KLCI likely to extend loss as U.S.-China trade spat continues

2018-06-18 theedgemarkets
KUALA LUMPUR (June 19): The FBM KLCI is likely to extend its losses today as the U.S.-China trade spat continues with no immediate solution in sight.
2852 1562 0095 7123

1
Y&G, XingHe, MPCorp, BToto, Priceworth and CMS

2018-06-18 theedgemarkets
KUALA LUMPUR (June 18): Based on corporate announcements and news flow today, companies in focus on Monday (June 19) may include: Y&G Corp Bhd, XingHe Holdings Bhd, Malaysia Pacific Corporation Bhd, Berjaya Sports Toto Bhd, Priceworth International Bhd and Cahya Mata Sarawak Bhd.
2852 1562 0095 7123

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...